Immunovia Full Year report, January-December 2017
“The fourth quarter of 2017 marked an important inflection point for Immunovia in many aspects. We ended our final year of purely pre-commercial activity, and have now started what is planned as our first business year that will lead to the start of sales in the second half of 2018.” “During 2018 we expect to reach our target of starting commercial sales of IMMray™ PanCan –dby providing the test to customers, both private individuals and health organizations, so-calledself-pay customers.” “The internal work aimed at preparing the company for a listing on Nasdaq Stockholm’s main market